Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Intercept hit hard as FDA issues Ocaliva safety notice

Intercept hit hard as FDA issues Ocaliva safety notice

Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... Intercept can muster approvals in additional indications such as non-alcoholic steatohepatitis (NASH) for which it is in

Latest news

  • BMS claims a win in mid-stage NASH trial BMS claims a win in mid-stage NASH trial

    elafibranor and Intercept's Ocaliva (obeticholic acid), which is already on the market for another indication (primary biliary cholangitis).

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Intercept gets EU nod for rare liver disease therapy. Ocaliva approved as a combination treatment for primary biliary cholangitis. ... Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    The company is vying with rivals such as Allergan and Intercept Pharmaceuticals in its pursuit of the NASH market. ... Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and Tobira

  • CHMP backs Intercept's rare liver disease drug CHMP backs Intercept's rare liver disease drug

    CHMP backs Intercept's rare liver disease drug. Ocaliva on track for EU approval as analysts predict blockbuster sales. ... While PBC is a small indication, Intercept is also developing Ocaliva for non-alcoholic steatohepatitis (NASH) or fatty liver

  • Biologics set to revolutionise the gastrointestinal market Biologics set to revolutionise the gastrointestinal market

    Both have been forecast by the GBI Research analysts to become blockbuster drugs by 2022, along with Intercept's Ocaliva (obeticholic acid), which received FDA approval for the treatment of primary

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia